Background: Coronary heart disease (CHD) in the UK affects $3 million people, with4100 000 deaths annually. Mortality rates have halved since the 1980s, but annual NHS treatment costs for CHD exceed £2 billion. Aim: To examine the cost-effectiveness of specific CHD treatments in England and Wales. Methods: The IMPACT CHD model was used to calculate the number of life-years gained (LYG) from specific cardiological interventions from 2000 to 2010. Cost-effectiveness ratios (costs per LYG) were generated for each specific intervention, stratified by age and sex. The robustness of the results was tested using sensitivity analyses. 
Introduction
Coronary heart disease (CHD) generates a major disease burden in the UK, chronically affecting over 2.6 million individuals, and causing over 100 000 deaths annually. 1 However, CHD mortality in the UK has halved since the 1980s, as in most developed countries. Studies using a range of methodologies consistently suggest that some 40-50% of this fall can be attributed to medical treatments. [2] [3] [4] [5] [6] NHS costs for CHD are rapidly rising, and now exceed £2 billion annually, 7 having increased from £1.73 billion in 1999. 8 Hospital in-patient care now accounts for over £1 billion and drug treatment over £750 million, with some two-thirds going to patients aged 465 years. 7, 8 The 1998 CHD National Service Framework has led to a dramatic spending increase on revascularization, statins and other expensive medications, together exceeding £700 million. 9 In 2005, the statin bill alone exceeded £840 million. 10 Inevitably, these escalating costs have increased concerns about the most cost-effective use of limited NHS resources. 7, 11 Many economic evaluations of CHD interventions have been published. [12] [13] [14] [15] [16] However, much of the available economic evidence now appears restricted in focus or increasingly dated. It is therefore difficult for planners and policy makers to make valid comparisons across the wide range of available cardiac interventions. In fact, very few economic studies have used consistent methodology and assumptions to evaluate more than a handful of therapies simultaneously. The most recent comprehensive European analysis, in 1996, 12 suggested substantial variations in costeffectiveness ratios across different technologies, from £50 per life-year gained (LYG) for aspirin as secondary prevention, to £8240 per LYG for statins in primary prevention. 12 However, since then, most costs have increased substantially while statin costs have fallen dramatically, making the previous findings obsolete. Furthermore, the 1996 analysis did not consider potentially costly revascularization procedures. Earlier UK and US studies had suggested that the cost effectiveness of coronary artery bypass graft (CABG) surgery for chronic angina might vary between £2000 and £20 000 per LYG (or QALY), depending on patient selection and disease severity. 14, 15 Studies have consistently suggested that angioplasty is less cost-effective than CABG, generally exceeding £5000 per LYG. 14, 17 CABG surgery and angioplasty rates in Britain have trebled since the mid 1990s, and now dominate local and national CHD budgets. 9 Meanwhile, commentators increasingly suggest that scarce NHS resources should be directed to those interventions offering best value for money, to maximize the allocative efficiency of the health system. 7, 11, 18 This is equally true for decisionmakers at local or national levels, whether working in the National Institute for Health and Clinical Excellence (NICE) or in a Primary Care Trust (PCT). Hence there is a pressing need for a standardized approach to facilitate valid comparisons across the very wide range of interventions now potentially available to treat CHD patients.
This study therefore aimed to use a consistent methodology to examine the cost-effectiveness of all the principal CHD treatments given in England and Wales in 2000.
Methods
To capture all the important CHD treatments given in England and Wales in 2000, we identified and analysed 36 condition-treatment scenarios. The principal conditions were: acute myocardial infarction (AMI), secondary prevention after AMI or revascularization, unstable angina, chronic angina, heart failure in hospital and in the community, plus primary prevention using statins.
The specific therapies considered included aspirin, thrombolysis, beta-blockers, ACE inhibitors, statins, cardiac rehabilitation, warfarin, heparin, glycoprotein IIb/IIIa inhibitors, CABG surgery and angioplasty. Lifestyle interventions such as smoking cessation and diet will be considered in a separate study.
The IMPACT model
This large cell-based mortality model, previously validated in Scotland, New Zealand and Finland, has been described in detail elsewhere. [3] [4] [5] [19] [20] [21] [22] In brief, the model uses large MS Excel spreadsheets to synthesize data from: CHD patient numbers, uptake of specific medical and surgical treatments, effectiveness of specific treatments, and median survival in patients with and without CHD. The model was developed using data from a range of sources describing England and Wales in the year 2000. 3 The complete IMPACT model also includes the mortality consequences of population trends in major risk factors; these will be studied in a separate analysis. The effectiveness estimates for each therapy were based on recent meta-analyses and large randomized controlled trials. The included trials are listed in Appendix 2.
For the purpose of this study, the current IMPACT model was extended to follow each cohort of patients who received specific treatments for up to 10 years from the year 2000 through to 2010. Age-specific mortality rates, age-specific incidence rates, disease fatality and treatment efficacy (quantified as relative risk reduction) were used to calculate the number of deaths prevented or postponed in each patient group attributable to that treatment. 3, 20 Life-years gained (LYG) were calculated by applying median survival values for each group to the deaths prevented or postponed. 23 These LYG estimates were then used to calculate cost-effectiveness ratios, as detailed below. Results were stratified by age and sex.
Costing methodology
The perspective adopted for the study was that of the NHS. Only drug costs and intervention costs were included in this analysis. Cost-effectiveness ratios were calculated in terms of cost per LYG.
Unit costs for health technologies were estimated using a range of sources, including NHS Reference Costs, British National Formulary (BNF), Prescription Cost Analysis (PCA) data, published literature, NICE Guidance documents and grey literature. 18, [24] [25] [26] [27] [28] The costs used in base-case analysis and the assumptions are summarized in Table 1 .
For drugs, the unit costs were derived from the BNF for 2000, 26 using the doses reported in the major trials (Appendix 2). Costs were adjusted for under-dosing where data were available.
There was considerable variation in costs across different formulations within the same class of drugs. For example, the annual cost of treatment with beta-blockers varied between £22 (atenolol) and £357 (carvedilol), depending on the drug of choice. For the base case estimates, weighted average costs were therefore calculated reflecting each drug's share in the UK drug prescription total. The breakdown of NHS expenditure according to each formulation was obtained from PCA data, which provide an accurate estimate of the drugs prescribed in the community settings. As there were few reliable data on hospital prescription patterns, we assumed similar drug use patterns in in-patient settings.
Costs for CABG surgery and angioplasty were taken from NHS Reference Costs for 2000. 25 Where possible, the data from routine cost sources were confirmed using other published sources, grey literature and policy documents. Costs of glycoprotein IIb/IIIa inhibitors and thrombolysis were taken from NICE reviews that used a rigorous costing methodology. 27 Cost of cardiac rehabilitation was taken from the published literature. 28 Oneoff costs were calculated for surgical procedures, cardiac rehabilitation, thrombolysis and glycoprotein IIIa/IIb inhibitors. [25] [26] [27] Wherever possible, the actual 2000 prices were used in the analysis. When the 2000 prices were not available, the prices were converted using the NHS Pay and Prices Index. When wide variations between drug doses and unit costs were encountered, the impact of cost variations on the costeffectiveness ratios was examined using sensitivity analyses.
All costs and treatment effects were estimated for 10-year age bands and for both men and women. The very small number of patients aged <35 years were excluded from the analysis, as were those aged 485 years. 3 
Time frame
Interventions for acute myocardial infarction and acute coronary syndrome were evaluated over a one-year scenario. Cardiac rehabilitation benefits were assumed to last for two years. Cost-effectiveness ratios were calculated on the basis of a 10-year time horizon for continuous drug interventions, in all chronic conditions except heart failure. Given the severely reduced life expectancy in heart failure, costs and treatment benefits were calculated over 2 years for patients admitted to hospital, and over 5 years for heart failure patients treated only in the community. 23 A discount rate of 3.5% was applied to both costs and benefits, as recommended by the National Institute for Clinical Excellence. 29 'Discount rates' can be defined as rates of discount used to convert future healthcare costs and benefits into equivalent present values. The impact of the discount rates on the results was tested in sensitivity analyses.
Sensitivity analyses
Sensitivity analyses are commonly used methods for assessing the robustness of an economic model by examining the changes in results of the analysis when key variables are varied over a specified range. Our sensitivity analyses were performed using a standard one-way methodology. 30 This addressed the uncertainties surrounding the key variables (treatment costs, patient numbers, treatment uptake, treatment efficiency, median survival and the overlap between different treatment categories). The reported base-case cost-effectiveness ratios were calculated using the best estimates for costs and effectiveness. The minimum and maximum plausible values for each variable (Table 1 and . 23 The largest contributions came from secondary prevention following myocardial infarction or revascularization, heart failure treatments and initial treatments for acute myocardial infarction (Table 2) .
Cost-effectiveness ratios

Acute myocardial infarction
All initial treatments had very favourable costeffectiveness ratios across all age groups (Figure 1 ). Base-case cost-effectiveness ratios were £408 per LYG for cardiopulmonary resuscitation (ranging from £192 in patients aged 45-54 years, to £1281 in patients aged 475 years), £1498 per LYG for thrombolysis (£1185-£1708 per LYG), and £268 per LYG for ACE inhibitors (£189-£560 per LYG). The least favourable cost-effectiveness was £7571 per LYG for primary angioplasty (£6054-£12 057 per LYG) ( Figure 1 and Table 3 ).
Secondary prevention
Cost-effectiveness was also very favourable for all secondary prevention treatments in patients following myocardial infarction or revascularization. Discounted base-case cost-effectiveness ratios for aspirin, beta blockers and warfarin were £885, £502 and £1075 per LYG, respectively. These findings were consistent across all age groups (Figure 1 ). Exercise-based rehabilitation, ACE inhibitors and statins were progressively more expensive, costing £1957, £3398 and £4246 per LYG. respectively ( Figure 1 , Table 3 ).
Chronic angina therapies
Aspirin proved a reasonably cost-effective treatment for chronic angina across all age groups (£1236-£2591 per LYG). The cost effectiveness ratios were two-to three-fold higher for revascularization treatments; between £3239 and £4601 per LYG for CABG surgery and between £3845 and £5889 per LYG for angioplasty, and up to ten-fold higher for statins (£11 978-£25 101) ( Figure 1 , Table 3 ).
Unstable angina
Aspirin, alone or in combination with low molecular weight heparin, was extremely cost-effective for unstable angina in all age groups, at <£500 per LYG. However, platelet glycoprotein IIb/IIIa inhibitors were up to ten-fold as expensive, irrespective of age, costing between £2257 and £4615 per LYG (Table 3) . Heart failure Aspirin, beta blockers and spironolactone all proved extremely cost-effective in the treatment of chronic heart failure, both for patients initially admitted to hospital and those treated in the community (Figure 1 ). The cost-effectiveness ratios were consistently <£700 per LYG across all age groups. ACE inhibitors were slightly more expensive, averaging £2173 per LYG for hospital patients and £2237 per LYG for community patients (Table 3) .
Statins for primary prevention
The cost-effectiveness ratio across all age groups was £27 828 per LYG. However, both age and sex had a powerful effect. Statins were extremely expensive in the youngest age groups (men aged 35-44, £69 373 per LYG), but cost-effectiveness improved with age, reaching £9159 per LYG in those few eligible men aged 75-84 years. Corresponding costs were even higher in women (£10 455-£94 645 per LYG) (Figure 2 ).
Expected total costs to the NHS
Discounted incremental costs and benefits showed a comparable spectrum, ranging from £58 per LYG (aspirin for unstable angina) to £27 828 per LYG (Statins for primary prevention) ( Table 4) .
Sensitivity analyses
The relative cost-effectiveness of specific treatments remained consistent, irrespective of whether maximum or minimum estimates were used (Figure 1 ). The largest variation in cost-effectiveness estimates were observed for primary PTCA and statins for primary prevention. These, however, represent extreme scenarios based on LYG calculations. For all other treatments, sensitivity analyses consistently generated cost-effectiveness ratios of <£30 000 per LYG ( Figure 1 ).
Discussion
Medical and surgical treatments for CHD in the UK now cost over £2 billion annually; 1 economic analyses are thus crucial. This is the first UK-based cost-effectiveness analysis since the mid 1990s to use a standardized methodology to compare the cost effectiveness of diverse cardiological treatments. Furthermore, it is comprehensive, including all standard therapies used in 2000. The data were based on the entire adult population in England and Wales and are therefore not subject to sampling errors. Data quality was generally good or adequate. Furthermore, the underlying IMPACT modelling methodology has now been replicated in a number of countries. [3] [4] [5] [19] [20] [21] [22] The cost-effectiveness levels for cardiological treatments considered in this analysis varied by over 100-fold. Aspirin and betablockers (for myocardial infarction, secondary prevention, angina or heart failure) were generally extremely cost-effective, with cost-effectiveness ratios of <£1500 per LYG. Other secondary prevention therapies (rehabilitation, warfarin and ACE inhibitors) also appeared cost-effective, at <£5000 per LYG. However, many eligible patients were actually not receiving the appropriate treatments. They represent an important target for the CHD NSF programme. 9 Revascularization for angina or myocardial infarction also demonstrated relatively favourable costeffectiveness levels, ranging from around £4000 per LYG (for chronic angina treatment) to approximately £7500 per LYG (for primary PTCA) over a 10-year period. Revascularization may also represent one of the most potent therapies for suitable patients with impaired left ventricular function.
However, cost-effectiveness for statins was more mixed, ranging from £3000 per LYG in heart failure patients, to almost £70 000 per LYG for primary prevention in younger subjects.
Comparison with other studies
The cost-effectiveness of statin treatment has been studied extensively. 12, 13, 16, [32] [33] [34] Our results are generally consistent with those of previous UK-based studies, 12, 13 bearing in mind that unit costs for statins almost halved between 1996 (£550 per annum) and 2000 (£387 per annum). The estimated cost-effectiveness of statins for primary prevention was previously reported as £5100-12 500 per LYG in the UK, and US$8100-40 000 per QALY in the USA, depending on the annual risk of CHD. 12, 13, 16, 32 Total costs will be substantial, if 15-25% of adults are treated, as recently suggested. 35 Our estimates for ACE inhibitors ranged from approximately £2000 per LYG for heart failure patients up to £3500 for secondary prevention patients. This is consistent with the estimated cost effectiveness of ramipril (£4000 per LYG in high-risk groups at 5 years, decreasing to £100 per LYG for lifetime treatment). Aspirin treatment proved to be consistently very cost-effective across different disease groups and age groups in our analysis, with cost effectiveness ratios of £60 to £900 per LYG. This is consistent with UK work, 12, 13 but contrasts with one surprisingly high estimate from Gaspoz et al. in the USA. 37 Cost-effectiveness ratios were slightly higher for revascularization, averaging £4000 per LYG for CABG surgery and £4500 for angioplasty. Previous estimates have ranged from £2000-20 000 per LYG or QALY. 14, 15, 17 These remain relatively costeffective when compared with many other treatments funded within the NHS, such as renal dialysis, or some forms of cancer chemotherapy approaching the (rather generous) NHS cost-effectiveness threshold value of £30 000 per QALY. 29, 38 Reassuringly, our cost-effectiveness estimates are generally consistent with the published literature. Furthermore, the sensitivity analysis suggested that the results were reasonably robust. The relative costeffectiveness of specific treatments remained fairly consistent, irrespective of whether best maximum or minimum estimates for treatment efficacy, life expectancy and unit costs were used.
Results were based on 2000 costs. The price of statins should progressively reduce due to patent expiration; however, the transition to generics may be slow.
Limitations of this study
The primary aim of this paper was to compare a range of therapies using a standard methodology. We therefore focused on average net treatment costs for each life year gained. We did not explicitly capture reductions in admissions, follow-up visits, costs associated with adverse events or potential costs avoided (such as further infarcts, or further revascularisation). The use of more complex modelling techniques, while theoretically desirable, was not feasible. However, that approach certainly represents a future research target. Meanwhile, evidence suggests that the inclusion of long-term cost consequences in other studies may make surprisingly little difference. 13 Each treatment relative risk value in the model was based on a metaanalysis comparison with an older therapy, or in some cases with placebo if relevant. A perfect economic analysis for informing optimal resource allocation in the health system would use data from real-life clinical practice and the treatment-mix offered to patients, to establish a common baseline. While not ideal, the IMPACT Model produced an approximation to this, by recognizing that most patients in most groups were receiving multiple therapies.
Implications for research and clinical care
Earlier analyses intriguingly suggested that preventative strategies are consistently more cost-effective than treating established disease. [39] [40] [41] Further studies are now indicated, using standardized methodology to measure the cost-effectiveness of risk factor reductions across the entire spectrum of primary and secondary prevention.
The implications for clinicians and policy makers are clear. CHD funding in the NHS currently seems to emphasize revascularization and waiting lists. Over 90% of NSF monies have been spent on pathways to revascularization, (promoting referral and assessment), and on the high-cost procedures themselves. 9 However, in the UK as in other countries, secondary prevention and heart failure therapies still consistently offer better value for money than CABG surgery, angioplasty or statins.
